Skip to main content
. 2018 Apr 18;2018:8926598. doi: 10.1155/2018/8926598

Table 4.

Overall response rate for doxorubicin monotherapy and combination therapy.

Best overall response A single agent (n = 38), no. (%) Combination therapy (n = 37), no. (%)
Complete response 0 (0) 3 (8)
Partial response 4 (11) 8 (22)
Overall response 4 (11) 11 (30)
Stable disease 19 (50) 12 (32)
Progressive disease 14 (37) 13 (35)
Not evaluable or not assessed 1 (3) 1 (3)